NCT06761599

Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 214 (actual)
• Sponsor: Superior University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Pulmonary toxicity during Hodgkin lymphoma treatment is significant for a variety of reasons, ranging from clinical care to therapeutic innovation and patient outcomes.

Detailed description

Understanding chemotherapy-induced pulmonary issues, particularly bleomycin-induced toxicity, might enhance treatment efficacy, side effects, and quality of life for Hodgkin lymphoma patients. For Hodgkin lymphoma chemotherapy patients with pulmonary difficulties, which result in significant patient morbidity and mortality, early detection, proactive surveillance, and rapid management are required. Identifying the prevalence, risk factors, and clinical signs of pulmonary toxicity helps clinicians stratify treatment.

Conditions

• Hodgkin Lymphoma

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	group 1	To determine treatment-induced pulmonary toxicity prevalence and risk factors in Hodgkin lymphoma patients during chemotherapy or radiation therapy.

Timeline

• Start date: 2024-02-18
• Primary completion: 2024-07-15
• Completion: 2025-03-01
• First posted: 2025-01-07
• Last updated: 2025-01-07

Locations

1 site across 1 country: Pakistan